Nektar Therapeutics Investor Relations Material
Latest events
Q1 2025
Nektar Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Nektar Therapeutics
Access all reports
Nektar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of novel therapies. These therapies aim to selectively modulate the immune system to treat autoimmune disorders, chronic inflammatory conditions, and cancer.The company uses proprietary PEGylation and advanced polymer conjugate technologies to modify the chemical structure of substances, facilitating the development of new drug candidates. It is headquartered in San Francisco, California, and its shares are listed on the NASDAQ under the ticker symbol NKTR.
Key slides for Nektar Therapeutics
Study Update
Nektar Therapeutics
Study Update
Nektar Therapeutics
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
NKTR
Country
🇺🇸 United States